LXRX - Lexicon Pharmaceuticals, Inc.
5.51 0.00 (0.00%)
After hours: 5:16PM EST
| Previous Close | 5.34 |
| Open | 5.36 |
| Bid | 5.31 x 2900 |
| Ask | 5.53 x 1000 |
| Day's Range | 5.30 - 5.52 |
| 52 Week Range | 4.26 - 13.97 |
| Volume | 579,476 |
| Avg. Volume | 671,811 |
| Market Cap | 583.647M |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.25 |
| Earnings Date | Feb 20, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
- ACCESSWIRE•4 hours ago
SHAREHOLDER ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019
NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon" ...
- ACCESSWIRE•9 hours ago
Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) Bronstein, Gewirtz & Grossman, LLC Class Action Update
NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...
- GlobeNewswire•yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX
If you are a shareholder who purchased Lexicon securities between March 11, 2016, and January 17, 2019, you have until April 1, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
- Zacks•yesterday
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•yesterday
Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•5 days ago
3 Top Diabetes Stocks to Watch in February
Innovative insulin pumps and promising drugs make these three companies worthy of investors' attention.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX
NEW YORK, NY / ACCESSWIRE / February 17, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. (''Lexicon'' or the ''Company'') (LXRX) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of Texas, and indexed under 19-cv-00301, is on behalf of a class consisting of all behalf of persons and/or entities who purchased or otherwise acquired Lexicon securities between March 11, 2016 and January 17, 2019, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE•7 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX) & Lead Plaintiff Deadline: April 1, 2019
NEW YORK, NY / ACCESSWIRE / February 15, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon" ...
- ACCESSWIRE•7 days ago
Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR) Bronstein, Gewirtz & Grossman, LLC Class Action Update
NEW YORK, NY / ACCESSWIRE / February 15, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can ...
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX
If you are a shareholder who purchased Lexicon securities between March 11, 2016, and January 17, 2019, you have until April 1, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
- PR Newswire•8 days ago
Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.
NEW YORK , Feb. 14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment ...
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II (AMR)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
- GlobeNewswire•9 days ago
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
